Dosimetric Risk Factors for Acute Radiation Pneumonitis in Patients With Prior Receipt of Immune Checkpoint Inhibitors

Brief report: Four-year survival with durvalumab after chemoradiotherapy in Stage III NSCLC – an update from the PACIFIC trial

(2021) Corinne Faivre-Finn et al.   Journal of Thoracic Oncology

Incidence, Risk Factors, and CT characteristics of Radiation Recall Pneumonitis induced by Immune Checkpoint Inhibitor in Lung Cancer

(2021) François Cousin et al.   RADIOTHERAPY AND ONCOLOGY

Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer

(2021) Salma K. Jabbour et al.   JAMA Oncology

Lung Stereotactic Body Radiation Therapy and Concurrent Immunotherapy: A Multicenter Safety and Toxicity Analysis

(2020) Sibo Tian et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Immune-related Pneumonitis Following Chemoradiotherapy and Subsequent Immune Checkpoint Blockade in Unresectable Stage III Non-Small-Cell Lung Cancer

(2020) Jarushka Naidoo et al.   Clinical Lung Cancer

Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer

(2020) Shirish Gadgeel et al.   JOURNAL OF CLINICAL ONCOLOGY

Radiographic patterns of symptomatic radiation pneumonitis in lung cancer patients: Imaging predictors for clinical severity and outcome

(2020) Richard Thomas et al.   LUNG CANCER

Re-irradiation in the thorax - An analysis of efficacy and safety based on accumulated EQD2 doses

(2020) C. Schröder et al.   RADIOTHERAPY AND ONCOLOGY

Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials

(2020) Willemijn S M E Theelen et al.   Lancet Respiratory Medicine

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

(2019) Barbara Burtness et al.   LANCET

Safety of Combined Immunotherapy and Thoracic Radiation Therapy: Analysis of 3 Single-Institutional Phase I/II Trials

(2018) Vivek Verma et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non–Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial

(2017) Stephen G. Chun et al.   JOURNAL OF CLINICAL ONCOLOGY

Pneumonitis in cancer patients receiving anti-PD-1 and radiotherapies

(2017) Chieh-Sheng Lu et al.   MEDICINE

Radiation Dose–Volume Effects in the Lung

(2010) Lawrence B. Marks et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Stereotactic body radiation therapy: The report of AAPM Task Group 101

(2010) Stanley H. Benedict et al.   MEDICAL PHYSICS